Uloric Dosing Updated to Include Patients with Severe Renal Impairment

Urloric is indicated for the chronic management of hyperuricemia in patients with gout
Urloric is indicated for the chronic management of hyperuricemia in patients with gout

The labeling for Uloric (febuxostat; Takeda) has been updated to include new dosing information for patients with severe renal impairment.

Uloric, a xanthine oxidase inhibitor, is indicated for the chronic management of hyperuricemia in patients with gout. Previously, the drug labeling did not include dosing recommendations for patients with severe renal impairment (CrCl <30mL/min) as there was insufficient data to make a recommendation apart from exercising caution in these patients.

The new labeling now recommends patients with severe renal impairment be limited to a dose of 40mg once daily. The recommendation for patients with mild to moderate renal impairment continues to be the same (no dosage adjustment necessary).

Related Articles

In addition, the prescribing information states that Uloric has not been studied in end stage renal impairment patients who are on dialysis.

Uloric is available in 40mg and 80mg strength tablets.

For more information visit takeda.us.